Kolmar Introduced Treatment for Atopic Dermatitis
Published: 2004-12-27 06:55:00
Updated: 2004-12-27 06:55:00
Following the Korea Food and Drug Administration (KFDA)’s recent approval on pharmaceutical bioequivalence of the generic drugs, Korea Kolmar announced its successful development of a medication for treatment of atopic dermatitis (AD).
Using a non-steroid based active ingredient known as bupex...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
